US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Zealand Pharma
< Previous
1
2
3
4
5
6
Next >
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
June 22, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
June 22, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
June 15, 2026
From
Zealand Pharma
Via
GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
June 10, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
June 08, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
June 08, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
June 07, 2026
From
Zealand Pharma
Via
GlobeNewswire
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity
June 05, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
June 02, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
June 01, 2026
From
Zealand Pharma
Via
GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 29, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
May 27, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
May 27, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
May 26, 2026
From
Zealand Pharma
Via
GlobeNewswire
Resolutions from Zealand Pharma's Extraordinary General Meeting 2026
May 26, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
May 14, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma - Execution framework for share buy-back program
May 07, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Three Months of 2026
May 07, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
May 07, 2026
From
Zealand Pharma
Via
GlobeNewswire
The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting
May 01, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
May 01, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
April 30, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
April 29, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
April 28, 2026
From
Zealand Pharma
Via
GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
April 22, 2026
From
Zealand Pharma
Via
GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
April 19, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
April 19, 2026
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
April 14, 2026
From
Zealand Pharma
Via
GlobeNewswire
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
March 31, 2026
From
Zealand Pharma
Via
GlobeNewswire
Resolutions from Zealand Pharma's Annual General Meeting 2026
March 26, 2026
From
Zealand Pharma
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
